Day: November 1, 2024

MONTVALE, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird’s 54th Annual Global Industrial Conference on November 13, 2024. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition...

New data show tolerability and no evidence of spreading to blood or tissues even at high doses of Tonix’s attenuated live-virus, minimally replicating vaccine candidate TNX-801 in immunocompromised animals TNX-801, has characteristics that align closely with the World Health Organization’s (WHO) preferred target product profile (TPP) criteria for mpox vaccines WHO-declared public health emergency of international concern (PHEIC)1-4: Mpox cases of the new clade Ib mpox detected in Sweden, Thailand, Singapore, India, Germany and England TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with clade I monkeypox and is in development as an mpox vaccine CHATHAM, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical...

PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November.Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ET Jefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMTA live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednesday, November 13, 2024. About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused...

Electrochem divestiture makes Integer a pure-play medical technology company PLANO, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced the completion of the previously announced sale of its Electrochem business to Ultralife Corporation for $50 million in cash. Integer will use the proceeds from the sale to pay down outstanding debt. “With the divestiture of Electrochem, Integer is now a pure-play medical technology company with additional capital to deploy in high-growth medtech markets,” said Joseph Dziedzic, Integer President & CEO. “I would like to thank the Electrochem team for all their contributions over the years. We think Electrochem has a bright future under the ownership of Ultralife.” To...

LAS VEGAS, Nov. 01, 2024 (GLOBE NEWSWIRE) —  Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, announced today that it plans to release its financial results for the third quarter ended September 30th, 2024, on November 8th, 2024, aftermarket. Planet 13 will host a conference call on November 8, 2024, to discuss its third quarter financial results and provide investors with key business highlights, strategy, and outlook. The call will be chaired by Bob Groesbeck, Co-CEO, Larry Scheffler, Co-CEO, and Dennis Logan, CFO. CONFERENCE CALL DETAILS Date: November 8, 2024 | Time: 5:00 p.m. ET Call registration link – available 15 minutes before call: Link Webcast link: Link About Planet 13 Planet 13 (https://planet13.com) is a vertically integrated...

ATLANTA, Nov. 01, 2024 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) today reported results for the third quarter ended September 30, 2024. Results shown are from continuing operations. When referring to any comparative period, all metrics are pro forma for continuing operations of the combined business of Chart and Howden (pro forma excludes the following businesses that were divested in 2023: Roots, American Fan, Cofimco and Cryo Diffusion). The Howden acquisition closed on March 17, 2023. Third quarter 2024 highlights compared to third quarter 2023, pro forma:Orders of $1.17 billion, an increase of 5.4% Sales of $1.06 billion, an increase of 22.4% Reported gross margin of 34.1%, an increase of 350 basis points (“bps”) Reported operating income of $178.5 million (16.8% of sales) or $235.9 million when adjusted for...

Third Quarter 2024 HighlightsNet income: $573 million, $617 million excluding identified items(a) Diluted earnings per share: $1.75 per share; $1.88 per share excluding identified items EBITDA: $1.2 billion Cash from operating activities: $670 million Returned $479 million to shareholders through dividends and share repurchases Creating long-term value through progress toward LYB’s sustainability targets:Started construction of MoReTec-1 catalytic advanced recycling facility in Germany Exceeded 2030 renewable electricity targetHOUSTON and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) — Comparisons with the prior quarter and third quarter 2023 are available in the following table: Table 1 – Earnings SummaryMillions of U.S. dollars (except share data)   Three Months Ended Nine Months Ended  September 30,2024 June...

EUROCASTLE INVESTMENT LIMITED                                      Contact:        Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Hannah CrockerTel: +44 1481 723450         Eurocastle Announces Resignation of Mr. Peter Smith from Board of Directors Guernsey, 1 November 2024 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) today announces that after 13 years of valuable service, Mr. Peter Smith retired as a non-independent director of the Company, effective 30 October 2024. We are deeply grateful for Mr. Smith’s dedication and contributions over the years. The Board is currently in the process of considering a replacement for Mr. Smith. ABOUT EUROCASTLE Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company. On 8 July 2022, the Company announced the...

Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. “The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals – driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation of operational efficiencies, and maintaining a cost-disciplined approach as we drive our business to profitability,” said Scott Hutton, CEO...